Mpox Vaccination Update: Intradermal or Subcutaneous Regimen Permitted

The U.S. Department of Health and Human Services (HHS) and the CDC have updated the mpox provider agreement to allow for both an intradermal and subcutaneous route of administration to be used for mpox vaccination. There is reported vaccine hesitancy due to concern over possible hyperpigmentation or scarring following intradermal administration. This change highlights that concerns about intradermal administration should not be a barrier to vaccination.

At the height of the outbreak, the intradermal route was preferred because it increased the number of available vaccine doses, while safely providing a similar immune response against mpox. However, mpox providers now have the flexibility to offer the intradermal or subcutaneous regimen based on optimal vaccine use and acceptance, feasibility of administration, and available vaccine supply. Both subcutaneous and intradermal vaccine regimens provide a safe immune response against mpox.

For more information view the CDC’s interim clinical considerations for JYNNEOS.

Thank you for the work you are doing to promote vaccination against mpox in Philadelphia.

View the Mpox Vaccination Program Provider Agreement.

Mpox Website

The PDPH Mpox website is here! Visit the page for everything you need to offer Mpox vaccine at your site. The page includes information on:

• Enrolling as a provider
• Ordering vaccine
• Vaccine administration
• Reporting wastage

Visit the Mpox Page

Why the name change?

The World Health Organizations (WHO) announced this week that they are phasing out the use of the term “monkeypox.” The change was prompted by observation of racist and stigmatizing language online, in other settings, and in some communities when the outbreak expanded earlier this year.

In line with the WHO recommendation, the Philadelphia Immunization Program and CDC is phasing out use of the term “monkeypox” and will use the new term “mpox” going forward. This change from the WHO will enhance the U.S. response to mpox by using a less stigmatizing term. We appreciate your understanding as our team works to implement this change throughout the related documents, forms and webpages.

Have questions?

Please contact Kenya Mack, our Adult Coordinator, at Kenya.Mack@phila.gov.

MPOX Eligibility: Anyone At Risk Can Be Vaccinated

• Have had multiple or anonymous sex partners in the past 14 days.
• Have had any newly diagnosed STI in the past 12 months, including gonorrhea, chlamydia, early syphilis, or HIV.
• Have recently attended or plan to attend any venue where anonymous sex or sex with multiple partners will occur (e.g. saunas, bathhouse, sex clubs, sex parties).
• Have met recent partners or plan to meet new partners through social media platforms (such as Grindr, Tinder or Scruff), or at clubs, raves, sex parties, saunas).

Monkeypox Vaccine Deliveries Paused for Thanksgiving

Monkeypox vaccine deliveries will be paused during the week of Thanksgiving, November 21 – 25, 2022. The last delivery for monkeypox vaccine will be on Monday, November 21. 

Ordering will remain open this week until Thursday, by 5pm. Remember to submit your temperatures to tempcheck@phila.gov and complete a reconciliation of vaccine on hand for your order to be approved.

Click the button below to submit your order request for monkeypox vaccine.

Deliveries for monkeypox vaccine will resume on the week of November 28.

Thank you for keeping Philadelphia safe and healthy! If you have any questions, please contact Kenya Mack at Kenya.Mack@phila.gov. 

Monkeypox Provider Survey

The Philadelphia Health Department is looking to identify provider offices and clinics that administer monkeypox JYNNEOS vaccine to non-patients and offer walk-in hours. If you are a monkeypox vaccine provider, please fill out the brief survey.

V-Safe for Monkeypox Vaccine: Survey to Assess Promotion Willingness and Perceived Barriers

The Immunization Safety Office at CDC will soon be going live with a monkeypox module in CDC’s v-safe After Vaccination Health Checker. V-safe is a voluntary smartphone-based system that uses text messaging and web surveys to provide personalized and confidential health check-ins. Participants can tell CDC how they, or their child or dependent, feel after they receive a monkeypox vaccine.

Based on the success of v-safe for COVID-19, the CDC has found that promoting and encouraging enrollment at the vaccine delivery site is the best way to make vaccine recipients aware of v-safe. Please fill out this short survey to assess willingness and perceived barriers to promotion of v-safe at your practice.

Become a Monkeypox Vaccine Provider 

• Gay, bisexual, transgender, non-binary, and other men who have sex with men, transgender, or non-binary persons

• Have had multiple or anonymous sex partners in the last 14 days
• Have had any newly diagnosed STI in the past 12 months, including gonorrhea, chlamydia, early syphilis, or HIV
• Have recently attended or plan to attend any venue where anonymous sex or sex with multiple partners will occur (e.g. saunas, bathhouses, sex clubs, sex parties)
• Have met recent partners or plan to meet new partners through social media platforms (such as Grindr, Tinder or Scruff), or at clubs, raves, sex parties, saunas

• Sex workers (of any sex or gender), and/or
• Anyone with known close contact (skin-to-skin) with someone with monkeypox in the past 14 days

Monkeypox Vaccine Update: Expanded Eligibility

Become a Monkeypox Vaccine Provider

• Gay, bisexual, transgender, non-binary, and other men who have sex with men, transgender, or non-binary persons

AND meet one of the following criteria:

• Have had multiple or anonymous sex partners in the last 14 days
• Have had any newly diagnosed STI in the past 12 months, including gonorrhea, chlamydia, early syphilis, or HIV
• Have recently attended or plan to attend any venue where anonymous sex or sex with multiple partners will occur (e.g. saunas, bathhouses, sex clubs, sex parties) in the next 30 days
• Have met recent partners or plan to meet new partners in the next 30 days through social media platforms (such as Grindr, Tinder or Scruff), or at clubs, raves, sex parties, saunas

• Sex workers (of any sex or gender), and/or
• Anyone with known close contact (skin-to-skin) with someone with monkeypox in the past 14 days